Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenFleet Therapeutics (Shanghai) (HKSE:02595) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
GenFleet Therapeutics (Shanghai) Net Margin % Related Terms
GenFleet Therapeutics (Shanghai) Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) Net Margin % Chart
GenFleet Therapeutics (Shanghai) Annual Data
Trend
Dec23
Dec24
Dec25
Net Margin %
-689.40
-647.21
-1,377.58
GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Net Margin %
0.00
0.00
-218.08
-787.21
-2,639.30
HKSE:02595 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenFleet Therapeutics (Shanghai) Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s Net Margin % distribution charts can be found below:
* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) (HKSE:02595) has a Net Margin % of -2,639.30% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #765 out of 944 companies in the Biotechnology industry, placing it in the top 81%.
Is GenFleet Therapeutics (Shanghai)'s Net Margin % too high?
GenFleet Therapeutics (Shanghai)'s current Net Margin % is -2,639.30%. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #765 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #765 out of 944 companies for Net Margin %. This places GenFleet Therapeutics (Shanghai) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Net Margin % is -2,639.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HKSE:02595) has a current Net Margin % of -2,639.30%. The current Net Margin % is -2,639.30%. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HKSE:02595), the current Net Margin % is -2,639.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
10GF Score
Get the complete analysis for HKSE:02595
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02595 has been successfully added to your 
